Navigation Links
Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008
Date:2/14/2008

36,192,017 42,129,557

COMMITMENTS AND CONTINGENCIES -- --

SHAREHOLDERS' EQUITY:

Preferred stock, $0.001

par value, 5,000,000

shares authorized,

no shares issued and

outstanding -- --

Common stock, $0.001 par

value, 100,000,000 shares

authorized, 19,069,805 and

18,875,000 shares issued and

outstanding as of

December 31, and June 30,

2007, respectively 19,070 18,875

Paid-in capital 19,669,847 19,163,549

Statutory reserves 1,735,484 1,735,484

Retained earnings 15,267,766 9,885,670

Accumulated other

comprehensive income 2,239,649 826,998

Total shareholders' equity 38,931,816 31,630,576

Total liabilities and

shareholders' equity $ 75,123,833 $ 73,760,133

SHENGTAI PHARMACEUTICAL INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME

FOR THE SIX AND THREE MONTHS ENDED DECEMBER 31, 2007 AND 2006

(UNAUDITED)

Three months ended Six months ended

December 31, December 31,

2007 2006 2007 2006

SALES REVENUE $ 24,954,288 $ 12,310,489 $ 44,327,357 $ 22,909,810

COST OF SALES 19,086,274 9,237,442 33,865,306 17,397,319

GROSS PROFIT 5,868,014 3,073,047 10,462,051 5,512,491

SELLING, GENERAL

AND ADMINISTRATIVE

EXPENSES 1,814,376 958
'/>"/>

SOURCE Shengtai Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Shengtai Pharmaceutical, Inc. Reports Record 2007 Annual Results
2. Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008
3. Shengtai Pharmaceutical, Inc. to Present at Roth Capital Phoenix Conference
4. Shengtai Pharmaceutical, Inc. to Present at Roth Conference
5. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
6. BD to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
9. MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
10. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
11. Cardinal Health CEO of Clinical & Medical Products to Speak at Merrill Lynchs Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... 01, 2015 Indiana Fiber Network, ... Provider, announces NewWays Networking, LLC (NewWays) selected IFN ... with IFN, NewWays is well positioned to scale ... for Internet bandwidth in rural parts of Indiana,” ... to Cory Childs IFN Enterprise Sales Manager, IFN ...
(Date:3/1/2015)... CrossFit Attollo is a CrossFit gym located in Vancouver ... to new members. Now through the end of March ... will receive their fourth month half off. , ... The three month contract is only $264, dropping the price ... comes in at only $55. The special saves new members ...
(Date:2/28/2015)... 28, 2015 In a recent episode ... of Game Change Athlete Development Services and ... the benefits of athlete development and player engagement during ... unique challenges that athletes face and how off-field activities ... , Fletcher became involved in athlete development issues while ...
(Date:2/28/2015)... The Classic Denture Center , located ... Throughout all of March patients can receive $25 ... service can help overall mouth health and give ... notice certain symptoms that suggest the denture teeth are ... , 1.    Pain, clicking, and popping in the joints, 2.    Pain ...
(Date:2/28/2015)... Indosoft Inc , developers of Q-Suite, a ... to announce the development of Q-Suite 5.9. Building off ... Q-Suite, this new version will include enhancements to existing ... to the leading edge call center software. General availability ... features to enhance security and protection. Administrators will be ...
Breaking Medicine News(10 mins):Health News:NewWays Networking Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2
... has praised South Africa's malaria control programme,// saying the country's ... ,Wolfowitz visited the village of Mamitwa in ... malaria incidence ¯ last week (15 March). ... here is that this area has achieved one of the ...
... York University College of Dentistry research team has found ... to caries (tooth decay) and periodontal (gum) disease.// ... an Associate Professor of Epidemiology & Health Promotion and ... the largest-ever study on the oral health of immigrants ...
... fluids hold promise as a potential alternative to blood as ... cancers can be detected through the analysis of oral fluids. ... to detect meaningful amounts of disease markers in oral fluids, ... as in blood. Proteomics is a relatively new method of ...
... enamel is the hardest tissue produced by the body. It ... of cells that is lost by the time the tooth ... its lifetime vulnerable to wear, damage, and decay. // ... prospect of artificially growing enamel, or even whole teeth, using ...
... engineering has emerged as a promising alternative for ... tissues, circumventing the complications associated with traditional transplants.// ... regenerate damaged tissue by using engineered tissue substitutes ... integrate into the host tissue. ...
... tests and biopsy, saliva can be used to detect ... ~4 million American, 90% being women. pSS patients are ... develop lymphoma, a fatal lymphocytic cancer. ,Scientists at ... of salivary biomarkers that can distinguish pSS patients from ...
Cached Medicine News:Health News:World Bank Head Praises DDT Use Against Malaria 2Health News:Study Links Tooth Decay and Gum Infections to Ethnicity and Country of Origin 2Health News:Scientists Re-grow Dental Enamel from Cultured Cells 2
(Date:2/27/2015)... Feb. 27, 2015  Pomerantz LLP is investigating claims ... or the "Company") (NASDAQ: VTAE ).  Such ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... of its officers and/or directors have violated Sections 10(b) ... On February 27, 2015, the Company ...
(Date:2/27/2015)... -- Acsis Inc., the market leader for supply chain visibility, ... John DiPalo , Acsis, Chief Strategy Officer, has been ... 2015 Provider Pro to Know. The award recognizes ... prepare their companies, and customers, supply chains for the ... of Provider Pros to Know is featured in ...
(Date:2/27/2015)... , Israele, February 27, 2015 ... nel suo sviluppo dell,innovativo sistema di monitoraggio dell,infarto ... primo trial sull,uomo-     ... nello sviluppo di nuovo sistema per il monitoraggio ... (CHF), ha annunciato oggi di aver concluso una ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2
... the 2007 ... Chemotherapy Foundation Symposium, BOULDER, Colo., Nov. 9 Pharmion ... Phase 2 trial of,Amrubicin in second-line chemo-sensitive small cell lung ... II inhibitor currently in development for the,treatment of SCLC. These ...
... improvement in disease activity observed through 2.5 years of ... a Phase 2 continuation trial -, - No observed increase ... malignancies and infections over 2.5 years of LymphoStat-B treatment -, ... HGSI ) today announced the presentation of Phase 2 ...
Cached Medicine Technology:Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 2Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 3Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 4Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 5Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus 8
The OX-2 is configured asstandalone or handheld unit, designed for hospital, transport and home use....
Rad-9™...
... 8600 Series Tabletop/Portable Digital Pulse ... tool for patient monitering. From ... the 8600 has earned the ... and is recognized for its ...
... Medicals ONE™ technology is the ... uses a patented digital sensor ... an analog sensor. Dolphin ONE™ ... the signal in the sensor, ...
Medicine Products: